TPTatyana Nikolaevna Proskokova

Tatyana Nikolaevna Proskokova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tatyana Nikolaevna Proskokova has a total of 42 co-authors. Here are the top co-authors by number of shared publications:

  • Dmitriy V. I

    Khabarovsk Center for the Development of Psychology and Childhood «Psylogia

    5 shared publications
  • Nadezhda V. Vyalova

    Far Eastern State Medical University, Ministry of Health of the Russian Federation, Khabarovsk, Russia, Russian Federation

    3 shared publications
  • И Дмитрий Витальевич

    ФГБОУ ВО «Дальневосточный государственный медицинский университет» Минздрава России; КГАНОУ «Хабаровский центр развития психологии и детства «Псилогия

    3 shared publications
  • Aleksandr M. Khelimskiy

    Far-Eastern State Medical University, Ministry of Health of the Russian Federation

    2 shared publications
  • Denis S. Doloka

    Far-Eastern State Medical University, Ministry of Health of the Russian Federation

    2 shared publications
  • Olga Alekseevna Efremova

    Belgorod State National Research University

    2 shared publications

Latest Publications

  • Open Access

    Global developmental delay with psychotic disorder at onset of late-infantile form of Niemann-Pick disease type C: A case report

    by Dmitriy V. I, Tatiana N. Proskokova, И Дмитрий Витальевич

    Niemann-Pick disease type C (NP-C) is a rare, progressive, autosomal recessive neurodegenerative disorder with onset at various ages, caused by pathogenic variants in the NPC1 or NPC2 genes. In the late-infantile form of NP-C, the development of psychotic symptoms at onset or during the course of the disease in preschool children has not been described in the literature. We report a clinical case of a 6-year-old female patient who, from the first days of life, had prolonged jaundice, hepatosplenomegaly and haemorrhagic episodes. Early development was age-appropriate, but from the age of 4 years speech regression began, and from the age of 5 years progressive behavioral disturbances appeared. The key feature was the development of rare and severe psychotic symptoms at preschool age in the late-infantile form of NP-C: inappropriate laughing without reason, talking to a mirror, night wandering around the house, aggressive jealousy of a younger brother, grabbing a kitchen knife, self-aggression (scratching until bleeding), insomnia and withdrawal. Simultaneously, daytime enuresis, ataxia and upward gaze palsy – a pathognomonic sign of NP-C – appeared. Video-electroencephalography monitoring revealed epileptic encephalopathy with continuous spike-and-wave activity during sleep with a pharmacoresistant course. Whole-exome sequencing identified compound heterozygous mutations c.3019CG + c.3742_3745delCTCA in NPC1, and blood oxysterol levels were markedly elevated. Subsequently, pathogenetic therapy with miglustat was initiated. Psychotic manifestations in NP-C can mimic childhood schizophrenia or psychotic disorder, but their combination with hepatosplenomegaly, ataxia and supranuclear gaze palsy should immediately direct the physician towards biochemical and genetic testing for NP-C.

  • Aicardi—Goutieres syndrome type 6 associated with a compound heterozygous variant in ADAR: a first case report in the Russian population

    by D.V. I, S.A. Seregin, T.N. Proskokova

    Aicardi-Goutieres syndrome (AGS) is a rare hereditary disorder with different types of inheritance manifested by progressive leukoencephalopathy with early onset, sharing common features with autoimmune disease. This article describes the first Russian case of AGS type 6 (AGS6) associated with compound heterozygote c.577C>G (p.Pro193Ala)+c.2304G>A (p.Trp768*) in ADAR and provides a more in-depth understanding of AGS6 by summarizing the worldwide literature and suggesting models for practitioners to diagnose patients with clinically suspected AGS.

  • Open Access

    Clinical markers of cognitive impairment in patients with chronic heart failure of ischemic origin during out-patient regular follow-up: a cross-sectional study

    by Olga A. Efremova, Oksana V. Dudchenko, Ludmila A. Kamyshnikova, Tatiana N. Proskokova, Olga A. Bolkhovitina, Ekaterina V. Lysenko

    Background: Cognitive impairment (CI) is present in 25–50% of chronic heart failure (CHF) patients. Doctors who monitor patients with cardiovascular disorders do not have clearly set criteria for their referral to a neurologist in case of suspected CI. Therefore, CHF patients do not receive treatment for CI on time. Aim: To identify significant clinical markers of CI in patients with CHF of ischemic origin. Materials and methods: This cross-sectional cohort study included 134 patients with CHF of ischemic origin (mean age 63.36 ± 10.63 years; men, 76.12%), who were regularly monitored in a municipal polyclinic. All patients were tested for CI with the Montreal Cognitive Assessment Scale (MoCA); basic hemodynamic parameters, lipid profile, brain natriuretic peptide (NT-proBNP) were assessed, and triglyceride-glucose index (TyG) and body mass index (BMI) were calculated. Cardio-ankle vascular index (CAVI) was measured, echocardiography and a 6-minute walk test (SMWТ) were performed and past history of CHF, arterial hypertension (AH) and diabetes mellitus (DM) was collected. Results: CI (MoCA score ≤ 25) was detected in 85 (63.43%) outpatients with CHF of ischemic origin; the group without CI (MoCA score 26) included 49 (36.67%) patients. There were significant correlations between MoCA and CAVI scores (partial correlation coefficient, r = -0.802, p 0.001; adjusted squared multiple correlation coefficient (adj. R2) = 0.881, p 0.001), MoCA and TyG (r = -0.357, p = 0.029; adj. R2 = 0.363, p 0.001), MoCA and SMWТ (r = -0.211, p = 0.037; adj. R2 = 0.696, p 0.001). The multivariate test for significance of planned comparisons between CAVI and MoCA scores (Wilks' lambda) was 0.005 (F = 4.74; p 0.001). Conclusion: CAVI, TyG and SMWТ values are the clinical markers of CI in patients with CHF of ischemic origin. There is a direct association between increased CAVI and the presence of CI, regardless of age, lipid metabolism parameters, structural and functional heart parameters, CHF duration, AH and DM. Identification of these markers could be an indication for an in-depth assessment of CHF patients by a neurologist.


  • Phelan—McDermid syndrome associated with a novel heterozygous mutation in the SHANK3 gene

    by D.V. I, T.N. Proskokova

    Синдром Фелан—МакДермид (СФМ) — это наследственное заболевание, ассоциированное с микроделецией хромосомы 22q13 или точковыми мутациями в гене SHANK3, характеризующееся задержкой психического и речевого развития, интеллектуальной недостаточностью, эпилепсией и расстройством аутистического спектра (РАС). Представлено наблюдение пациентки с СФМ, ассоциированным с гетерозиготной мутацией c.2486delC (p.Pro829fs) в гене SHANK3. В нашем наблюдении диагностический путь пациентки с СФМ занял более 7 лет, поводом для обращения стал дебют эпилептических приступов и нарушение речевого развития. Существование различных типов перестроек и геномных вариаций может объяснить высокую клиническую вариабельность, наблюдаемую у пациентов с СФМ. Только молекулярная диагностика может точно поставить диагноз у лиц с СФМ для последующего наблюдение и медико-генетического консультирования семей.

  • Open Access

    Clinical Exome Sequencing in Patients with Undifferentiated General Developmental Delay and Intellectual Disabilities

    by Dmitriy V. I, Viktoriya A. Ioksha, Tatyana N. Proskokova, И Дмитрий Витальевич

    Introduction. Each fifth neurodevelopmental disorder is diagnosed in massively parallel sequencing only. Objective: to present the experience of exome sequencing in children with undifferentiated general developmental delay and intellectual disabilities. Materials and methods. We assessed 33 patients (19 males and 14 females) at the age of 4.5 2.4 years with general developmental delay and intellectual disabilities. We studied patients' medical and family histories and their neurological statuses as well as the findings of neuropsychological testing and clinical exome sequencing. Results.The effectiveness of clinical exome sequencing in the sample was 39.4% (MECP2, WDR45, SYNJ1, ADAR, PMM2, SHANK3, KMT5B, UBE3A, PTPN11, CTNNB1, and MTOR mutations). The pathogenic variants were significantly more prevalent in the patients with motor development delay, 53.8% of patients (P .05). Most incident conditions included insomnias (46.2%), autism spectrum disorders (38.5%), developmental regression (38.5%), and epilepsy (38.5%). Genetic disorders were more common in the female patients . Conclusion. With the study results, we can suppose that ca. 40% of patients with undifferentiated general developmental delay and intellectual disabilities had genetic disorders and, therefore, needed further evaluation with molecular genetic testing.

  • Open Access

    Phenotypic features of a Russian family with spinocerebellar ataxia type 6 from Khabarovsk Krai

    by Tatyana N. Proskokova, Dmitry V. I., Natal’yA B. Serdyuk, Natal’yA Yu. Abramycheva, И Дмитрий Витальевич

    The article presents a familial case of spinocerebellar ataxia type 6, consisting of 7 people across 4 generations from a mixed marriage of Yakut, Even, and Russian ethnicities, living in Khabarovsk Krai. The mutant allele of the CACNA1A gene had 27 stable CAG repeats in all patients (normal is <18 CAG repeats), while the normal allele had 13 CAG repeats. Clinical features included rapidly progressing cerebellar ataxia in males (0.96–9.00 points per year on the SARA scale); presence of psychological disorders in the form of alcoholism, early-onset binge drinking, completed suicidal behaviors; life expectancy reduced in 2 patients to 27 and 36 years.

  • Clinical-genealogical and molecular-genetic features of spinocerebellar ataxia type 1 in the Khabarovsk Region

    by Dmitriy Vitalyevich I, Tatyana Nikolaevna Proskokova, Natalia Vladimirovna Sikora

    The clinical picture of SCA1 in the Khabarovsk Region is characterized, along with cerebellar symptoms, by more frequent manifestations of pyramidal, extrapyramidal, cognitive, autonomic and psychiatric disorders. The age of patients was 34,1 ± 4,2 years, and the age of disease onset was 31,4 ± 2,3 years. The number of CAG-repeats in the ATXN1 gene varied from 43 to 63. The non-mutated ATXN1 gene in the Khabarovsk Region population contained 29,0 ± 0,4 CAG-repeats. The prevalence of SCA1 in the Khabarovsk Region was 1:100 000 of the population which corresponds to the world prevalence of 1–3:100 000 of the population.


  • CANVAS is a common form of late-onset hereditary ataxia

    by Е. П. Нужный, Н. Ю. Абрамычева, Е. Г. Воробьева, Е. О. Иванова, Ю. А. Шпилюкова, А. И. Белякова-Бодина, Д. В. И, Т. Н. Проскокова, К. А. Шпилюкова, Е. Ю. Федотова, et al.

    Синдром CANVAS (мозжечковая атаксия, невропатия и вестибулярная арефлексия) - аутосомно-рецессивная атаксия с поздним дебютом, обусловленная носительством биаллельной экспансии (AAGGG)n во 2-м интроне гена RFC1. До настоящего момента отсутствуют сведения о распространенности данного заболевания в российских семьях. Нами был проведен поиск биаллельной экспансии AAGGG-повторов у 35 российских пациентов с поздней мозжечковой атаксией. Верифицированы 5 пациентов (14,3%) с синдромом CANVAS и характерной клинической картиной.


  • Content of selenium in the serum of patients with autosomal dominant spinocerebellar ataxia in the Khabarovsk region

    by Dmitriy I, Tatyana Proskokova, Natalya Yakusheva, Yuriy Kovalskiy, Aleksandr Khelimskiy

    In patients with autosomal dominant spinocerebellar ataxia (AD SCA), the level of selenium in the blood serum was lower by a factor of 1.6 than the result obtained in the control group. There is a weak correlation between the severity of ataxia and selenium content in the blood serum of patients with AD SCA, which possibly suggests the participation of selenium in the pathogenesis of the disease. Given the decrease in selenium content in blood serum in patients with AD SCA, it is probably advisable to include selenium preparations in the symptomatic therapy for these patients.